Knowledge about genomic recurrence risk testing among breast cancer survivors

Journal of Cancer Education

Volumn 26, Issue 4, 2011, Pages 664-669

  Lipkus, Isaac M ^a   Vadaparampil, Susan T ^b   Jacobsen, Paul B ^b   Miree, Cheryl A ^b  

^a DUKE UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Decision making; Genomic testing; Knowledge

Indexed keywords

ARTICLE; ATTITUDE TO HEALTH; BREAST TUMOR; DOCTOR PATIENT RELATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; GENOMICS; HUMAN; MIDDLE AGED; PATHOLOGY; PATIENT EDUCATION; PROGNOSIS; RISK ASSESSMENT; SURVIVOR; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; GENOMICS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PROGNOSIS; RISK ASSESSMENT; SURVIVORS;

EID: 84859916611     PISSN: 08858195     EISSN: 15430154     Source Type: Journal    
DOI: 10.1007/s13187-011-0248-5     Document Type: Article

References (11)

1. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312.
2. National Comprehensive Cancer Network (2011). Practice guidelines in oncology for breast cancer (Version 2.2011). National Comprehensive Cancer Network, Inc.
3. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, et al. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671-1676.
4. American Cancer Society (2010) Breast cancer profiler tool. Accessed 17 February 2011.
5. Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26(25):4063-4071.
6. Richman AR, Tzeng JP, Carey LA, Retel VP, Brewer NT (2011) Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 20(1):28-35.
7. Bernstam EV, Walji MF, Sagaram S, Sagaram D, Johnson CW, Meric-Bernstam F (2008) Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer 112(6):1206-1213.
8. Beaton C, Codd RJ, Holland PA, Gateley CA (2008) Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the Internet. The Breast Journal 14(4):366-368.
9. Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823-1829.
10. Thompson AM, Johnson A, Quinlan P et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279-287.
11. Slodkowska EA, Ross JS (2009) Mamma Print 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 9(5):417-422.